<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217671</url>
  </required_header>
  <id_info>
    <org_study_id>Kamada-AAT (inhaled) 007</org_study_id>
    <nct_id>NCT01217671</nct_id>
  </id_info>
  <brief_title>International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema</brief_title>
  <official_title>A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kamada, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kamada, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised , placebo controlled, double blind , multicentre, Phase II/III study&#xD;
      evaluating the safety and efficacy of Kamada AAT for inhalation in patients with Emphysema&#xD;
      caused by Alpha-1 Antitrypsin (AAT) deficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alpha-1 Antitrypsin Deficiency, also called Alpha-1-Proteinase Inhibitor (API) deficiency, is&#xD;
      a genetic disorder characterized by the production of an abnormal amount of AAT protein and&#xD;
      reduced circulating levels of this protein. Subjects with AAT deficiency are at increased&#xD;
      risk for developing Emphysema. It is believed that this is the result of the chronic activity&#xD;
      of elastase released by cells continually present in the lungs in low numbers.&#xD;
&#xD;
      Three blinded interim analyses have shown that there are no safety issues and no concerns&#xD;
      regarding tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exacerbation events and lung density</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Evaluations</measure>
    <time_frame>Approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Alpha-1 Antitrypsin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Kamada AAT for inhalation</intervention_name>
    <description>Alpha-1 Antitrypsin (AAT)</description>
    <arm_group_label>Alpha-1 Antitrypsin</arm_group_label>
    <other_name>Alpha-1 Proteinase Inhibitor (API)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Principal Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of emphysema confirmed by CT scan. If a report of past CT scan is not&#xD;
             available at site documenting then a CT scan is to be performed at screening&#xD;
&#xD;
          -  Male or female patients at least 18 years of age.&#xD;
&#xD;
          -  Able and willing to sign an informed consent.&#xD;
&#xD;
          -  Patient with record of congenital AAT deficiency of phenotype PiZZ (homozygote) or&#xD;
             other rare phenotypes related to AAT deficiency and with AAT serum level ≤ 11&#xD;
             micromole. For patients receiving IV AAT augmentation therapy the serum AAT level&#xD;
             threshold does not apply.&#xD;
&#xD;
          -  FEV1/SVC &lt;70% of predicted value post bronchodilator (SVC is slow VC) and FEV1 &lt; 80%&#xD;
             of predicted value post-bronchodilator&#xD;
&#xD;
          -  History of at least two moderate or severe exacerbations that required change in&#xD;
             treatment (antibiotics, systemic steroids, hospitalization) in the last 18 months&#xD;
             prior to date of screening , with at least one of these occurring within the last 12&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Ability to comply with completion of electronic diary.&#xD;
&#xD;
          -  Ability to self-administer inhaled AAT.&#xD;
&#xD;
          -  No significant abnormalities in serum hematology, serum chemistry and serum&#xD;
             inflammatory / immunogenic markers according to the Principal Investigator's judgment,&#xD;
             taking into considerations the potential effects of the AAT deficiency.&#xD;
&#xD;
          -  No significant abnormalities in urinalysis according to the Principal Investigator's&#xD;
             judgment, taking into considerations the potential effects of the AAT deficiency.&#xD;
&#xD;
          -  No significant abnormalities in ECG per investigator judgment.&#xD;
&#xD;
          -  Negative for HBsAg and for antibodies to HCV, HIV-1.&#xD;
&#xD;
          -  AAT deficient patients who are either naïve (not receiving IV augmentation therapy) or&#xD;
             AAT deficient patients (receiving IV augmentation therapy), if they have been stable&#xD;
             on regular therapy for at least 3 months prior to the screening visit and are willing&#xD;
             to continue the same regime throughout this trial. Note that only sites in Germany can&#xD;
             recruit patients who are currently being treated with IV AAT.Patients who stopped IV&#xD;
             augmentation treatment 6 months prior to screening date and will not re-start this&#xD;
             treatment for the course of the study will be considered Naïve.&#xD;
&#xD;
          -  Non-pregnant, non-lactating female patients, whose screening pregnancy test is&#xD;
             negative and who are using contraceptive methods deemed reliable by the investigator,&#xD;
             or who are at least 2 years post-menopausal or surgically sterilized.&#xD;
&#xD;
        Principal Exclusion Criteria:&#xD;
&#xD;
          -  FEV1 &gt;= 80% or FEV1 &lt; 20% of predicted value post-bronchodilator.&#xD;
&#xD;
          -  FEV1/SVC&gt;=70%&#xD;
&#xD;
          -  History of lung transplant.&#xD;
&#xD;
          -  Any lung surgery within the past two years.&#xD;
&#xD;
          -  On any thoracic surgery waiting list.&#xD;
&#xD;
          -  End of last exacerbation less than 6 weeks prior to screening/re-screening visit.&#xD;
&#xD;
          -  Clinically significant intercurrent illnesses (except for respiratory or liver disease&#xD;
             secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine,&#xD;
             neurological, hematological, neoplastic, immunological, skeletal or other) that in the&#xD;
             opinion of the investigator, could interfere with the safety, compliance or other&#xD;
             aspects of this study. Patients with well-controlled, chronic diseases could possibly&#xD;
             be included after consultation with the treating physician and the sponsor.&#xD;
&#xD;
          -  Active smoking during the last 12 months from screening date.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Woman of child-bearing potential not taking adequate contraception deemed reliable by&#xD;
             the investigator.&#xD;
&#xD;
          -  Presence of psychiatric/ mental disorder or any other medical disorder which might&#xD;
             impair the patient's ability to give informed consent or to comply with the&#xD;
             requirements of the study protocol.&#xD;
&#xD;
          -  Evidence of ongoing viral infection with HCV, HBV and/or HIV.&#xD;
&#xD;
          -  Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally&#xD;
             prescribed drugs.&#xD;
&#xD;
          -  IgA Deficiency&#xD;
&#xD;
          -  History of life threatening allergy, anaphylactic reaction, or systemic response to&#xD;
             human plasma derived products.&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to baseline visit.&#xD;
&#xD;
          -  Inability to attend scheduled clinic visits and/or comply with the study protocol.&#xD;
&#xD;
          -  Any other factor that, in the opinion of the investigator, would prevent the patient&#xD;
             from complying with the requirements of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Stolk, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC, Leiden, Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inspiration Research Limited</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seymour Health Centre</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Gieben und Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malmo University Hospital</name>
      <address>
        <city>Malmo</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/31467115</url>
    <description>PubMed</description>
  </link>
  <results_reference>
    <citation>Stolk J, Tov N, Chapman KR, Fernandez P, MacNee W, Hopkinson NS, Piitulainen E, Seersholm N, Vogelmeier CF, Bals R, McElvaney G, Stockley RA. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019 Nov 21;54(5). pii: 1900673. doi: 10.1183/13993003.00673-2019. Print 2019 Nov.</citation>
    <PMID>31467115</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary, Emphysema</keyword>
  <keyword>Alpha-1 Antitrypsin Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

